Study Group: Physicians who Treat Mantle Cell and NHL (US)(?)
Council Members in this Study Group: 83
Request a survey with this Study Group
Leading Experts in this Study Group
 |
What is a GLG Leader? |
Donald Fleming, MDDivision Head of Hematology and Oncology
Davis Health System, Inc.
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...
Taral Patel, MDOncologist
Mid Ohio Oncology Hematology Inc.
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at Dana Farber Cancer Institute in Boston, Massachusetts. His clinical focus is on lymphoma and is very involved in Phase II/III clinical trials for new compounds as well as stem cell transplantation.
Kenneth Algazy, MDClinical Professor of Medicine
University of Pennsylvania School of Medicine - CC
Dr. Kenneth Algazy, MD, is a Clinical Professor of Medicine at University of Pennsylvania School of Medicine. He is also a Section Chief in the Division of Hematology and Oncology at Philadelphia VA Medical Center. Dr. Algazy is involved in clinical trials in lung cancer, and interested in demographics...
Brian Abbott, MDMedical Director of Hematology
Big Sky Oncology
Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow...
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...
Assistant Professor of Medicine
University of Pennsylvania Cancer Center
Donald Tsai, MD, PhD, is an Assistant Professor of Medicine at the University of Pennsylvania Cancer Center. Dr. Tsai specializes in the treatment of hematological malignancies such as leukemia, multiple myeloma, lymphoma, Hodgkin's disease, myelodysplastic syndromes (MDS), and bone marrow transplantation....
Director of the Oupatient Hematology
THE NEW YORK-PRESBYTERIAN HOSPITAL
Michael Flamm, MD, PhD, is the Director of the Outpatient Hematology Clinic at the Columbia Presbyterian campus of the New York Presbyterian Hospital. He has expertise in the treatment of sickle cell anemia and paroxysmal nocturnal hemoglobinuria, and he also treats patients with hematologic malignancies...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Experts(?)
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
In a recent JCO article, Laptanib showed clinical efficacy and acceptable safety in a non-randomized trial involving newly diagnosed patients with advanced oe metastatic breast cancer. Larger trials are needed to confirm efficacy and explore if it is more potent than Genentech's Herceptin. For now,...
Avastin's recent FDA approval for m-breast cancer ( m-BCA) was lukewarm at best with no overall survival benefit yet and modest PFS data. European regulatory agencies usually require cost efficacy data and more strict data, which are not readily available for Roche/Genetech. The British market is not...
Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Director
- Partner
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms